United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$0.01 (+0.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Geron Corp Q2 loss per share $0.05
Wednesday, 3 Aug 2016 04:05pm EDT 

Geron Corp : Q2 loss per share $0.05 . Q2 revenue $211,000 . Geron corporation reports second quarter 2016 financial results and recent events . Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q2 revenue view $302,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
Wednesday, 16 Sep 2015 07:30am EDT 

Geron Corporation:Announces that it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.Says the site has commenced pre-screening hepatitis C patients and is led by principal investigator Parvez Mantry, a gastroenterologist and hepatologist.  Full Article

Geron Corp announces global strategic collaboration with Janssen to Develop and Commercialize Imetelstat
Thursday, 13 Nov 2014 04:15pm EST 

Geron Corp:Says it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses.Geron will receive an initial payment of $35 mln due after the applicable waiting periods under the Hart-Scott Rodino Act.And it is eligible to receive additional payments up to a potential total of $900 mln for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.  Full Article

BRIEF-Geron Corp and Janssen Pharmaceuticals enter into a license agreement

* On September 15, 2016, co, Janssen Pharmaceuticals Inc entered into a license agreement - SEC filing